ECSP045113A - Benzopiranos sustituidos como agonistas selectivos del receptor estrogenico beta - Google Patents

Benzopiranos sustituidos como agonistas selectivos del receptor estrogenico beta

Info

Publication number
ECSP045113A
ECSP045113A EC2004005113A ECSP045113A ECSP045113A EC SP045113 A ECSP045113 A EC SP045113A EC 2004005113 A EC2004005113 A EC 2004005113A EC SP045113 A ECSP045113 A EC SP045113A EC SP045113 A ECSP045113 A EC SP045113A
Authority
EC
Ecuador
Prior art keywords
selective agonists
benzopiranos
strogen
beta
receiver
Prior art date
Application number
EC2004005113A
Other languages
English (en)
Inventor
Jeffrey Alan Dodge
Venkatesh Gary Krishnan
Charles Willis Lugar Iii
Blake Lee Neubauer
Bryan Hurst Norman
Lance Allen Pfeifer
Timothy Ivo Richardson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP045113A publication Critical patent/ECSP045113A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

La presente invención se refiere a nuevos benzopiranos de cicloalquilo y derivados de los mismos, a composiciones que contienen estos compuestos, a su uso como agonistas selectivos del receptor estrogénico beta y a su uso en el tratamiento de enfermedades mediadas por el receptor estrogénico beta tales como cáncer de próstata, hiperplasia prostática benigna, cáncer testicular, cáncer de ovario, cáncer de pulmón, enfermedades cardiovasculares, trastornos neurodegenerativos, incontinencia urinaria, trastornos del sistema nervioso central (SNC), trastornos del tracto gastrointestinal (GI) y osteoporosis
EC2004005113A 2001-11-19 2004-05-19 Benzopiranos sustituidos como agonistas selectivos del receptor estrogenico beta ECSP045113A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33276601P 2001-11-19 2001-11-19
US36362202P 2002-03-11 2002-03-11

Publications (1)

Publication Number Publication Date
ECSP045113A true ECSP045113A (es) 2004-07-23

Family

ID=26988373

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005113A ECSP045113A (es) 2001-11-19 2004-05-19 Benzopiranos sustituidos como agonistas selectivos del receptor estrogenico beta

Country Status (23)

Country Link
US (1) US7217734B2 (es)
EP (1) EP1448544B1 (es)
JP (1) JP4381810B2 (es)
KR (1) KR100950616B1 (es)
CN (1) CN1312147C (es)
AT (1) ATE362471T1 (es)
AU (1) AU2002359283B2 (es)
CA (1) CA2467013C (es)
CY (1) CY1106726T1 (es)
DE (1) DE60220179T2 (es)
DK (1) DK1448544T3 (es)
EA (1) EA007382B1 (es)
EC (1) ECSP045113A (es)
ES (1) ES2286322T3 (es)
HR (1) HRP20040439A2 (es)
HU (1) HU229351B1 (es)
IL (3) IL161325A0 (es)
MX (1) MXPA04004703A (es)
NO (1) NO328563B1 (es)
NZ (1) NZ531850A (es)
PL (1) PL205733B1 (es)
PT (1) PT1448544E (es)
WO (1) WO2003044006A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7279499B2 (en) 2003-04-21 2007-10-09 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
EP1626974B1 (en) * 2003-04-21 2008-08-27 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
JP2008512458A (ja) 2004-09-07 2008-04-24 ワイス ６Ｈ−［１］ベンゾピラノ［４，３−ｂ］キノリン及びエストロゲン様物質としてのそれらの使用
ATE504582T1 (de) * 2004-10-18 2011-04-15 Lilly Co Eli Substituierte benzopyrane als selektive östrogenrezeptor-beta-agonisten
US20060166933A1 (en) * 2004-11-18 2006-07-27 Jain Nareshkumar F Novel 2H-chromene derivatives as selective estrogen receptor modulators
US8093302B2 (en) 2005-02-15 2012-01-10 Eli Lilly And Company Substituted tetralins as selective estrogen receptor-β agonists
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US8063102B2 (en) 2009-03-13 2011-11-22 N.V. Organon Tetrahydronaphthalen-2-ol derivatives
TW201043595A (en) 2009-03-13 2010-12-16 Organon Nv Tetrahydronaphthalen-2-ol derivatives
CN105960236A (zh) 2013-12-05 2016-09-21 卡罗医药股份公司 用于治疗间皮瘤的雌激素受体β激动剂
JP6978420B2 (ja) 2015-09-17 2021-12-08 オハイオ・ステート・イノヴェーション・ファウンデーション カルボラン化合物及びその使用方法
WO2021183760A1 (en) * 2020-03-11 2021-09-16 Ohio State Innovation Foundation Methods of modulating t-cell activation using estrogen receptor beta (erβ) agonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3901926A (en) * 1973-04-02 1975-08-26 Abbott Lab Alkylphenyl benzopyrans
EP0935000A3 (en) 1995-09-08 1999-09-08 Karo Bio Ab Orphan receptor
AU8102398A (en) * 1997-07-09 1999-02-08 Central Drug Research Institute (dl)-2,3-diaryl-2h-1-benzopyrans
US6593322B1 (en) 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
JP2003521468A (ja) 1999-03-17 2003-07-15 シグナル ファーマシューティカルズ， インコーポレイテッド エストロゲンレセプタを変調させるための化合物及び方法
TR200102992T2 (tr) 1999-04-16 2004-12-21 Astrazeneca Ab ß östrojen reseptörü ligandları.
CA2396059A1 (en) 1999-12-30 2001-07-12 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US7214706B2 (en) * 2000-03-01 2007-05-08 Akzo Nobel N.V. Chroman derivatives as estrogenic compounds
ES2293986T3 (es) 2000-03-27 2008-04-01 N.V. Organon Compuestos no esteroides tetraciclicos para tratamientos relacionados con el estrogeno.
GB2361642A (en) 2000-10-24 2001-10-31 Karobio Ab Estrogen receptor beta (ERbeta) agonists for use in cancer treatment
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TWI306450B (en) 2001-12-13 2009-02-21 Wyeth Corp Substituted phenyl naphthalenes as estrogenic agents
US6630508B1 (en) * 2002-02-11 2003-10-07 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor β agonists

Also Published As

Publication number Publication date
PL205733B1 (pl) 2010-05-31
NO20042583L (no) 2004-06-18
NO328563B1 (no) 2010-03-22
KR20040063963A (ko) 2004-07-15
US7217734B2 (en) 2007-05-15
HK1068349A1 (en) 2005-04-29
AU2002359283B2 (en) 2007-06-21
MXPA04004703A (es) 2004-08-19
PL374510A1 (en) 2005-10-31
JP4381810B2 (ja) 2009-12-09
DE60220179D1 (de) 2007-06-28
ES2286322T3 (es) 2007-12-01
IL161325A (en) 2008-07-08
IL161325A0 (en) 2004-09-27
HRP20040439A2 (en) 2005-04-30
CN1589268A (zh) 2005-03-02
US20040249167A1 (en) 2004-12-09
EA200400695A1 (ru) 2004-12-30
CY1106726T1 (el) 2012-05-23
IL185867A0 (en) 2008-01-06
KR100950616B1 (ko) 2010-04-01
EP1448544B1 (en) 2007-05-16
AU2002359283A1 (en) 2003-06-10
JP2005513027A (ja) 2005-05-12
NZ531850A (en) 2007-01-26
PT1448544E (pt) 2007-08-10
CN1312147C (zh) 2007-04-25
HUP0402628A2 (hu) 2005-04-28
HU229351B1 (en) 2013-11-28
EA007382B1 (ru) 2006-10-27
EP1448544A1 (en) 2004-08-25
CA2467013C (en) 2010-08-10
ATE362471T1 (de) 2007-06-15
CA2467013A1 (en) 2003-05-30
IL185867A (en) 2009-09-22
DE60220179T2 (de) 2008-02-07
WO2003044006A1 (en) 2003-05-30
DK1448544T3 (da) 2007-10-08
AU2002359283B8 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
PY0119496A (es) Compuestos heterociclicos como ligandos de receptores gabaa
GT200200266A (es) Uso de ureas de benzotiazoles
MXPA03005493A (es) Derivados de bencimidazol y piridilmidazol como ligandos para receptores gaba.
UY29317A1 (es) Derivados novedosos pirrolidilo de compuestos heteroaromáticos
ECSP034428A (es) Ciclopentanoindoles, composiciones conteniendo tales compuestos y su uso
GT200200148A (es) Compuestos de heteroarilo biciclicos fusionados substituidos con heteroarilo como ligandos del receptor gaba a
DE602004025460D1 (de) Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
IL185867A0 (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
MXPA04002070A (es) Compuestos de indazol sustituidos para el tratamiento de la inflamacion.
MXPA04002682A (es) Compuestos pirazolilo sustituidos para el tratamiento de la inflamacion.
PL2444085T3 (pl) Związki diarylohydantoinowe jako antagoniści receptora androgenów do leczenia raka
PA8583201A1 (es) Nuevos compuestos de pirazol como inhibidores del factor de crecimiento transformante (tgf)
CR20120119A (es) Moduladores del receptor glucocorticoide
CU23464B7 (es) (1,8)naftidirin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
CR9442A (es) Nuevos compuestos farmaceuticos
MXPA04002042A (es) Compuestos de bencimidazol sustituidos y su uso para el tratamiento del cancer.
SI1626974T1 (sl) Substituirani benzopirani kot selektivni agonistiestrogenskega receptorja beta
GT200500332A (es) Azabenzoxazoles para el tratamiento de trastornos del snc
PA8567701A1 (es) Agonistas del receptor b3-adrenergico
MX2008002366A (es) Antagonistas triciclicos fusionados de mglur1 como agentes terapeuticos.
BRPI0519201A2 (pt) moduladores de delta-opiàide tricÍclico
Li et al. 7-Cycloalkylcamptothecin derivatives: Preparation and biological evaluation
PA8633601A1 (es) Profarmacos de esteroides con accion androgenica
DE60140700D1 (de) Thienoi2,3-B pyridin-derivate als Antagonisten des Gonadotropin-freisetzenden Hormons
BR0112147A (pt) Tienopirrolidinonas